Based in Oxford, England, Oxford Sciences Innovation (OSI) specializes in investments in spin-outs from Oxford University’s technology, mathematical, physical, life sciences and medical sciences departments.
Oxford Nanopore’s goal is to enable the analysis of any living thing, by anyone,anywhere. The Company has developed the world's first and only nanopore DNA sequencing platform, which is uniquely scalable from pocket-sized formats through to ultra-high throughput devices.
Oxford Investment Consultants LLP is an investment advisor that covers life sciences, healthcare and technology in the United Kingdom. The firm prefers to make investments in the University of Oxford spin out companies. Oxford Investments Consultants LLP is based in the United Kingdom.
Moon Surgical, a pioneer in collaborative robotics, today announced that it has secured $31.3 million in Series A funding. The financing round was led by GT Healthcare Capital & Partners, with participation by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Cathay Health, and existing investor, Sofinnova Partners.
Read more ›
GT portfolio company Immunocore Holdings plc (Nasdaq: IMCR) announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), the most common primary cancer within the eye in adults.
Read more ›
GT portfolio announces the closing of a $75M series B round led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, and GT Healthcare Capital Partners also participated in the round.
Read more ›
